The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: Combining preclinical evidence with human Positron Emission Tomography (PET) studies

Frontiers in Neuroscience

Volumn 9, Issue FEB, 2015, Pages

  Terbeck, S ^a   Akkus, F ^b   Chesterman, L P ^c   Hasler, G ^b  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c Ansel Clinic Nottingham   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5;

ADDICTION; ARTICLE; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH; MOOD DISORDER; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NEUROBIOLOGY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; SLEEP; SOCIAL COGNITION; SOCIAL INTERACTION; SOCIAL STRESS;

EID: 84924423488     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00086     Document Type: Article

References (70)

1. Abe, T., Sugihara, H., Nawa, H., Shigemoto, R., Mizuno, N., Nakanishi, S. (1992). Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. Journal of Biological Chemistry, 267, 13361-13368.
2. Agid, Y., Buzsáki, G., Diamond, D.M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., et al. (2007). How can drug discovery for psychiatric disorders be improved? Nature Reviews. Drug Discovery, 6, 189-201.
3. Akkus, F., Ametamey, S.M., Treyer, V., Burger, C., Johayem, A., Umbricht, D., Hasler, G. (2013). Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C] ABP688 positron emission tomography. Proceedings of the National Academy of Sciences, 110, 737-742.
4. Akkus, F., Terbeck, S., Ametamey, S.M., Rufer, M.D., Treyer, V., Burger, C., Johayem, A., Gomez Mancilla, B., Sovago, J., Buck, A., Hasler, G. (2014). Metabotropic Glutamate Receptor 5 Binding in Patients with Obsessive-Compulsive Disorder. International Journal of Neuropsychopharmacology, in press.
5. Ametamey, S.M., Kessler, L.J., Honer, M., Wyss, M.T., Buck, A., Hintermann, S., Auberson, Y.P., Gasparini, F., Schubiger, P.A. (2006). Radiosynthesis and preclinical evaluation of11CABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. Journal of Nuclear Medicine, 47, 698-705.
6. Ametamey, S.M., Treyer, V., Streffer, J., Wyss, M.T., Schmidt, M., Blagoev, M., Hintermann, S., Auberson, Y., Gasparini, F., Fischer, U.C., Buck, A. (2007). Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. Journal of Nuclear Medicine, 48, 247-252.
7. Anderson, J. J., Bradbury, M. J., Giracello, D. R., Chapman, D. F., Holtz, G., Roppe, J.,. & Varney, M. A. (2003). In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3 H] 3-methoxy-5-(pyridin-2-ylethynyl) pyridine). European journal of pharmacology, 473, 35-40.
8. Ahnaou, A., Raeymaekers, L., Steckler, T., & Drinkenbrug, W. H. I. M. (2015). Relevance of the metabotropic glutamate receptor (mGluR5) in the regulation of NREM-REM sleep cycle and homeostasis: evidence from mGluR5 (-/-) mice. Behavioural brain research.
9. Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in neurosciences, 27, 370-377.
10. Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A.,. & Gomez-Mancilla, B. (2011). AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Movement Disorders, 26, 1243-1250.
11. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J.,. & Hagerman, R. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of medical genetics, 46, 266-271.
12. Bisaga, A., Danysz, W., Foltin, R.W. (2008). Antagonism of glutamatergic NMDA and mGluR5 receptors decrease consumption of food in baboon model of binge-eating disorder. European Neuropsychopharmacology, 18, 794-802.
13. Boer, K., Encha-Razavi, F., Sinico, M., Aronica, E. (2010). Differential distribution of group I metabotropic glutamate receptors in developing human cortex. Brain Research, 1324, 24-33.
14. Brennan, B.P., Rauch, S.L., Jensen, J.E., Pope, H.G. (2012). A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biological Psychiatry, 73, 31-24.
15. Brody, A.L. (2006). Functional brain imaging of tobacco use and dependence. Journal of Psychiatric Research, 40, 404-418.
16. Burket, J. A., Benson, A. D., Tang, A. H., & Deutsch, S. I. (2014). Rapamycin improves sociability in the BTBR mouse model of autism spectrum disorders. Brain research bulletin, 100, 70-75.
17. Chakrabarty, K., Bhattacharyya, S., Christopher, R., Khanna, S. (2005). Glutamatergic dysfunction in OCD. Neuropsychopharmacology, 30, 1735-1740.
18. Chiamulera, C., Epping-Jordan, M.P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., et al. (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neuroscience, 4, 873-874.
19. Chung, W., Choi, S. Y., Lee, E., Park, H., Kang, J., Park, H.,. & Kim, E. (2015). Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nature neuroscience.
20. Cleva, R. M., & Olive, M. F. (2011). Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules, 16, 2097-2106.
21. Deschwanden, A., Karolewicz, B., Feyissa, A.M., Treyer, V., Ametamey, S.M., Johayem, A., Burger, C., et al. (2011). Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. The American Journal of Psychiatry, 168, 727-734.
22. Durand, D., Pampillo, M., Caruso, C., Lasaga, M. (2008). Role of metabotropic glutamate receptors in the control of neuroendocrine function. Neuropharmacology, 55, 577-583.
23. Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2009). Open-label memantine in fragile X syndrome. Journal of autism and developmental disorders, 39, 1629-1635.
24. Erickson, C.A., Early, M., Stigler, K.A., Wink, L.K., Mullett, J.E., McDougle, C.J. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21, 565-569.
25. Everitt, B.J., Belin, D., Economidou, D., Pelloux, Y., Dalley, J.W., Robbins, T.W. (2008). Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 363, 3125-3135.
26. First, M.B., Gibbon, M. (1997). User's Guide for the Structured Clinical Interview for DSMIV Axis I Disorders SCID-I: Clinician Version.
27. Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 70-75.
28. Garber, K. B., Visootsak, J., & Warren, S. T. (2008). Fragile X syndrome. European Journal of Human Genetics, 16, 666-672.
29. Grove-Strawser, D., Boulware, M.I., Mermelstein, P.G. (2010). Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience, 170, 1045-1055.
30. Harvey, B.H., Shahid, M. (2012). Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacology, Biochemistry, and Behavior, 100, 775-800.
31. Hasler, G., LaSalle-Ricci, V. H., Ronquillo, J. G., Crawley, S. A., Cochran, L. W., Kazuba, D.,. & Murphy, D. L. (2005). Obsessive-compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. Psychiatry research, 135, 121-132.
32. Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007). Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of general psychiatry, 64, 193-200.
33. Hasler, G., van der Veen, J. W., Geraci, M., Shen, J., Pine, D., & Drevets, W. C. (2009). Prefrontal cortical gamma-aminobutyric acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biological psychiatry, 65, 273-275.
34. Hefti, K., Holst, S. C., Sovago, J., Bachmann, V., Buck, A., Ametamey, S. M.,. & Landolt, H. P. (2013). Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biological psychiatry,73, 161-168.
35. Hyman, S.E. (2005). Addiction: a disease of learning and memory. The American Journal of Psychiatry, 162, 1414-1422.
36. Hoffpauir, B. K., & Gleason, E. L. (2002). Activation of mGluR5 modulates GABAA receptor function in retinal amacrine cells. Journal of neurophysiology, 88, 1766-1776.
37. Hulka, L. M., Treyer, V., Scheidegger, M., Preller, K. H., Vonmoos, M., Baumgartner, M. R.,. & Quednow, B. B. (2014). Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Molecular psychiatry, 19, 625-632.
38. Kalivas, P.W., & Volkow, N.D. (2005). The neural basis of addiction: a pathology of motivation and choice. The American Journal of Psychiatry, 162, 1403-1413.
39. Kalivas, P.W. (2009). The glutamate homeostasis hypothesis of addiction. Nature Reviews. Neuroscience, 10, 561-572.
40. Krystal, J.H., Mathew, S.J., D'Souza, D.C., Garakani, A., Gunduz-Bruce, H., Charney, D. S. (2010). Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs, 24, 669-693.
41. Kupila, J., Kärkkäinen, O., Laukkanen, V., Tupala, E., Tiihonen, J., Storvik, M. (2012). mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study. Psychiatry Research,12, 149-155.
42. Koros, E., Rosenbrock, H., Birk, G., Weiss, C., and Sams-Dodd, F. (2007). The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 32, 562-576.
43. Koob, G.F., Volkow, N.D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 35, 217-238.
44. Lea, P.M., Faden, A.I. (2006). Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Reviews, 12, 149-166.
45. Legutko, B., Szewczyk, B., Pomierny-Chamiolo, L., Nowak, G., Pilc, A. (2006). Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacological Reports: PR, 58, 427-430.
46. Luykx, J.J., Laban, K.G., van den Heuvel, M.P., Boks, M.P.M., Mandl, R.C.W., Kahn, R.S., Bakker, S.C. (2012). Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neuroscience and Biobehavioral Reviews, 36, 198-205.
47. Meldrum, B.S. (2000). Glutamate as a neurotransmitter in the brain: review of physiology and pathology. Journal of Nutrition, 130, 1007.
48. Morris, S.E., Cuthbert, B.N. (2012). Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues in Clinical Neuroscience, 14, 29-37.
49. Olive, M.F. (2005). mGlu5 receptors: neuroanatomy, pharmacology, and role in drug addiction. Current Psychiatry Reviews, 1, 197-214.
50. Phan, K.L., Fitzgerald, D.A., Cortese, B.M., Seraji-Bozorgzad, N., Tancer, M.E., Moore, G.J. (2005). Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport, 16, 183-186.
51. Pittenger, C., Krystal, J.H., Coric, V. (2006). Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, 3, 69-81.
52. Pollack, M.H., Jensen, J.E., Simon, N.M., Kaufmann, R.E., Renshaw, P.F. (2008). High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam. Progress in Neuro-psychopharmacology and Biological Psychiatry, 32, 739-743.
53. Riaza Bermudo-Soriano, C., Perez-Rodriguez, M.M., Vaquero-Lorenzo, C., Baca-Garcia, E. (2012). New perspectives in glutamate and anxiety. Pharmacology, Biochemistry, and Behavior, 100, 752-774.
54. Riedel, G., Casabona, G., Platt, B., Macphail, E.M., Nicoletti, F. (2000). Fear conditioninginduced time- and subregion-specific increase in expression of mGlu5 receptor protein in rat hippocampus. Neuropharmacology, 39, 1943-1951.
55. Rutten, K., De Vry, J., Bruckmann, W., & Tzschentke, T. M. (2011). Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug and alcohol dependence, 114, 253-256.
56. Romano, C., van den Pol, A.N., O'Malley, K.L. (1996). Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution. The Journal of Comparative Neurology, 367, 403-412.
57. Rosenberg, D.R., Keshavan, M.S. (1998). Toward a neurodevelopmental model of obsessive-compulsive disorder. Biological Psychiatry, 43, 623-640.
58. Sanacora, G., Zarate, C.A., Krystal, J.H., Manji, H.K. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews. Drug Discovery, 7, 426-437.
59. Schoepp, D.D. (2001). Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. Journal of Pharmacological Experimental Therapy, 299, 12-20.
60. Segrin, C. (2000). Social skills deficits associated with depression. Clinical psychology review, 20, 379-403.
61. Simonyi, A., Schachtman, T.R., Christoffersen, G.R. (2010). Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. European Journal of Pharmacology, 639, 17-25.
62. Soares, D.P., Law, M. (2009). Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clinical Radiology, 64, 12-21.
63. Swanson, C.J., Bures, M., Johnson, M.P., Linden, A.-M., Monn, J.A., Schoepp, D.D. (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Reviews. Drug Discovery, 4, 131-144.
64. Szeszko, P.R., Christian, C., Macmaster, F., Lencz, T., Mirza, Y., Taormina, S.P., Easter, P., et al. (2008). Gray matter structural alterations in psychotropic drug-naive pediatric obsessivecompulsive disorder: an optimized voxel-based morphometry study. The American Journal of Psychiatry, 165, 1299-1307.
65. Tatarczynska, E., Klodzinska, A., Chojnacka-Wójcik, E., Palucha, A., Gasparini, F., Kuhn, R., Pilc, A. (2001). Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology, 132, 1423-1430.
66. Tronci, V., Vronskaya, S., Montgomery, N., Mura, D., Balfour, D.J.K. (2010). The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology, 211, 33-42.
67. Van den Heuvel, O.A., Remijnse, P.L., Mataix-Cols, D., Vrenken, H., Groenewegen, H.J., Uylings, H.B.M., van Balkom, A.J.L.M., et al. (2009). The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain, 132, 853-868.
68. Wagner, K. V., Hartmann, J., Labermaier, C., Häusl, A. S., Zhao, G., Harbich, D.,. & Schmidt, M. V. (2014). Homer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress. Neuropsychopharmacology.
69. Yüksel, C., Öngür, D. (2010). Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biological Psychiatry, 68, 785-794.
70. Zarei, M., Mataix-Cols, D., Heyman, I., Hough, M., Doherty, J., Burge, L.,. & James, A. (2011). Changes in gray matter volume and white matter microstructure in adolescents with obsessive-compulsive disorder. Biological psychiatry, 70, 1083-1090.